Lyell Immunopharma, Inc. (LYEL)
About Lyell Immunopharma, Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $36.0K
- Net income
- -$274.4M
- Total assets
- $340.1M
- Market cap
- $279.3M
- Operating margin
- -748344.4%
- Net margin
- -762355.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $36.0K
- Operating expenses
- $269.4M
- Operating income
- -$269.4M
- Income tax
- $0
- Net income
- -$274.4M
- EPS (basic)
- $-16.06
- EPS (diluted)
- $-16.06
Balance sheet
- Total assets
- $340.1M
- Current assets
- $260.9M
- Total liabilities
- $91.8M
- Current liabilities
- $49.4M
- Shareholders’ equity
- $248.2M
Cash flow
- Operating cash flow
- -$150.0M
- Investing cash flow
- $54.1M
- Financing cash flow
- $50.4M
- Net cash flow
- -$45.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $279.3M
- EPS (diluted)
- $-16.06
- Shares outstanding
- 22.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 17, 2021
Lyell Immunopharma, Inc. (LYEL) Stock Price
- Reported a net loss of $274.4M in FY2025.
- Revenue declined 100% from FY2021 to FY2025.
- Trading 67% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lyell Immunopharma, Inc..
Write a review
News about Lyell Immunopharma, Inc.
News & sentiment via Polygon.io
Lyell Immunopharma, Inc.: frequently asked questions
Is Lyell Immunopharma, Inc. an American company?
Lyell Immunopharma, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc. is headquartered in South San Francisco, California, United States.
Is Lyell Immunopharma, Inc. publicly traded?
Yes — Lyell Immunopharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol LYEL on the NASDAQ.
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
